Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma

Jia,Nan; Li,Qing; Tao,Xiang; Wang,Jieyu; Hua,Keqin; Feng,Weiwei

doi:10.3892/ol.2014.2437

Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma

Authors:
- Nan Jia
- Qing Li
- Xiang Tao
- Jieyu Wang
- Keqin Hua
- Weiwei Feng
View Affiliations

Affiliations: Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200090, P.R. China, Department of Pathology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200090, P.R. China
Published online on: August 12, 2014 https://doi.org/10.3892/ol.2014.2437
Pages: 2049-2054

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial carcinoma is the second most common gynecological malignancy of the female genital tract worldwide. Enhancer of zeste homolog 2 (EZH2), a critical component of the polycomb repressive complex 2, has been found to be involved in multiple biological processes and is overexpressed in several types of cancer. Previous studies have demonstrated that EZH2 is associated with endometrial carcinoma. The present study showed that EZH2 was overexpressed in complex hyperplasia, atypical hyperplasia and endometrial cancer, but not in simple hyperplasia and normal endometrium. Additionally, by analyzing the correlation between EZH2 expression and clinicopathological characteristics, the expression of EZH2 was found to be associated with myometrial invasion and lymph‑vascular space invasion of endometrial cancer. Furthermore, small interfering RNA was utilized to investigate the role of EZH2 in endometrial carcinoma cell proliferation, and the results showed that EZH2 knockdown suppressed the proliferation of endometrial carcinoma cells in vitro. Therefore, these findings indicate that EZH2 expression may predict a more aggressive biological behavior in endometrial carcinoma and it may provide potential therapeutic targets for treatment of endometrial carcinoma.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality wWorldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer; Lyon, France: 2010, http://globocan.iarc.fr. Accessed October 1, 2013
2	Sorosky JI: Endometrial cancer. Obstet Gynecol. 120:383–397. 2012.
3	Singh S, Raidoo S, Pettigrew G and Debernardo R: Management of early stage, high-risk endometrial carcinoma: preoperative and surgical considerations. Obstet Gynecol Int. 2013:7572492013.
4	Albertini AF, Devouassoux-Shisheboran M and Genestie C: Pathology of endometrioid carcinoma. Bull Cancer. 99:7–12. 2012.
5	Matias-Guiu X and Davidson B: Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch. 464:315–331. 2014.
6	Yoo KH and Hennighausen L: EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 8:59–65. 2012.
7	Choi JH, Song YS, Yoon JS, et al: Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS. 118:196–202. 2010.
8	Fan T, Jiang S, Chung N, et al: EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res. 9:418–429. 2011.
9	Lu C, Han HD, Mangala LS, et al: Regulation of tumor angiogenesis by EZH2. Cancer Cell. 18:185–197. 2010.
10	Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:624–629. 2002.
11	Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 100:11606–11611. 2003.
12	Weikert S, Christoph F, Köllermann J, et al: Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med. 16:349–353. 2005.
13	Bachmann IM, Halvorsen OJ, Collett K, et al: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 24:268–273. 2006.
14	Mannelqvist M, Stefansson IM, Wik E, et al: Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 12:169–175. 2012.
15	Eskander RN, Ji T, Huynh B, et al: Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer. 23:997–1005. 2013.
16	No authors listed. FIGO Committee for the Ethical Aspects of Human Reproduction and Women’s Health Committee Statement on Ethical Guidelines (Cairo, March 1998). J Obstet Gynaecol. 19:444–447. 1999.
17	Trimble CL, Method M, Leitao M, et al: Society of Gynecologic Oncology Clinical Practice Committee: Management of endometrial precancers. Obstet Gynecol. 120:1160–1175. 2012.
18	Samarnthai N, Hall K and Yeh IT: Molecular profiling of endometrial malignancies. Obstet Gynecol Int. 2010:1623632010.
19	Crea F, Fornaro L, Bocci G, et al: EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 31:753–761. 2012.
20	Liang BJ, Li XP, Lu J, et al: Effects of enhancer of zeste homolog (EZH2) downregulation on the proliferation and invasion of nasopharyngeal carcinoma cell and the possible mechanism. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 47:298–304. 2012.(In Chinese).
21	Wang C, Liu X, Chen Z, et al: Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma. Mol Carcinog. 52:229–236. 2013.
22	Leng L, Huang Q, Dong Y, et al: EZH2 gene silenced by siRNA suppresses the growth and invasion of endometrial carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao. 33:866–869. 2013.(In Chinese).
23	Lin YW, Ren LL, Xiong H, et al: Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer. J Pathol. 230:277–290. 2013.
24	Li H, Cai Q, Godwin AK and Zhang R: Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res. 8:1610–1618. 2010.
25	Zhou J, Roh JW, Bandyopadhyay S, et al: Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol. 128:344–348. 2013.